Greenwich LifeSciences, Inc.
GLSI
$22.23
$0.582.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 45.89% | -45.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.93% | 90.32% | |||
| Operating Income | 27.93% | -90.32% | |||
| Income Before Tax | 28.60% | -90.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.60% | -90.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.60% | -90.83% | |||
| EBIT | 27.93% | -90.32% | |||
| EBITDA | 27.94% | -90.32% | |||
| EPS Basic | 31.61% | -86.56% | |||
| Normalized Basic EPS | 31.59% | -86.59% | |||
| EPS Diluted | 31.61% | -86.56% | |||
| Normalized Diluted EPS | 31.59% | -86.59% | |||
| Average Basic Shares Outstanding | 4.40% | 2.27% | |||
| Average Diluted Shares Outstanding | 4.40% | 2.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||